Roche 454, SoftGenetics to Co-promote NGS Software Tools

May 09, 2012

|

NEW YORK (GenomeWeb News) – Roche 454 Life Sciences and SoftGenetics today said that they would co-promote next-generation sequencing software tools.

The alliance is aimed at providing users of 454's sequencing systems with next-generation sequencing data analysis options provided by SoftGenetics' NextGene software. The firms said the software can be used with 454 sequencing for a variety of applications including targeted amplicon resequencing, exome sequencing, transcriptome sequencing, and forensic profiling.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

More to Go Around

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

To Worry or Not?

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

Call for Ban

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

This Week in PLOS

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.

Featured White Papers

NGS is Accelerating Therapeutic Antibody Discovery - What Lies Beyond?

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Oct

11

Featured Webinar

Validation of Error-Corrected Sequencing for Hematological Malignancies

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Main menu